Newly Approved Antimicrobials

被引:2
作者
Cottreau, Jessica M. [1 ]
Christensen, Alyssa B. [2 ]
机构
[1] Rosalind Franklin Univ Med & Sci, Dept Pharm Practice, N Chicago, IL USA
[2] Providence Hlth & Serv, Infect Dis, Portland, OR USA
关键词
ACUTE BACTERIAL SKIN;
D O I
10.1097/NOR.0000000000000633
中图分类号
R47 [护理学];
学科分类号
1011 ;
摘要
In recent years, government-backed policies have promoted the development of new antimicrobials to combat increases in antibiotic-resistant organisms. This article summarizes the 10 new antibacterial agents to be approved in the last 5 years.
引用
收藏
页码:53 / 58
页数:6
相关论文
共 21 条
[1]  
Achaogen Inc, 2018, ZEMDR HIGHL PRESCR I
[2]  
[Anonymous], 2018, Eric Lafforgue/Art in All of Us
[3]  
[Anonymous], 2019, CLIN INFECT DIS
[4]  
[Anonymous], 2019, Antibiotic resistance threats in the United States
[5]  
Facta Farmaceutici, 2018, VAB HIGHL PRESCR INF
[6]   The 10 x '20 Initiative: Pursuing a Global Commitment to Develop 10 New Antibacterial Drugs by 2020 [J].
Gilbert, David N. ;
Guidos, Robert J. ;
Boucher, Helen W. ;
Talbot, George H. ;
Spellberg, Brad ;
Edwards, John E., Jr. ;
Scheld, W. Michael ;
Bradley, John S. ;
Bartlett, John G. .
CLINICAL INFECTIOUS DISEASES, 2010, 50 (08) :1081-1083
[7]  
GlaxoSmithKline Manufacturing, 2019, AV HIGHL PRESCR INF
[8]   Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties [J].
Jorgensen, Sarah C. J. ;
Mercuro, Nicholas J. ;
Davis, Susan L. ;
Rybak, Michael J. .
INFECTIOUS DISEASES AND THERAPY, 2018, 7 (02) :197-217
[9]   Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial [J].
Kollef, Marin H. ;
Novacek, Martin ;
Kivistik, Ulo ;
Rea-Neto, Alvaro ;
Shime, Nobuaki ;
Martin-Loeches, Ignacio ;
Timsit, Jean-Francois ;
Wunderink, Richard G. ;
Bruno, Christopher J. ;
Huntington, Jennifer A. ;
Lin, Gina ;
Yu, Brian ;
Butterton, Joan R. ;
Rhee, Elizabeth G. .
LANCET INFECTIOUS DISEASES, 2019, 19 (12) :1299-1311
[10]  
Melinta Therapeutics Inc, 2019, BAXD HIGHL PRESCR IN